Scarica l'app Stockscreener
40.51
2.32%
0.92
Dopo l'orario di chiusura:
40.51
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HRMY Giù?
Forum
Previsione
Precedente Chiudi:
$39.59
Aprire:
$39.91
Volume 24 ore:
959.03K
Relative Volume:
1.05
Capitalizzazione di mercato:
$2.33B
Reddito:
$772.53M
Utile/perdita netta:
$180.90M
Rapporto P/E:
13.06
EPS:
3.1024
Flusso di cassa netto:
$258.73M
1 W Prestazione:
+1.71%
1M Prestazione:
+20.78%
6M Prestazione:
+21.54%
1 anno Prestazione:
+27.15%
Intervallo 1D:
$39.23
$40.80
Intervallo di 1 settimana:
$38.12
$40.80
Portata 52W:
$25.52
$40.93
Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile
Nome
Harmony Biosciences Holdings Inc
Settore
Industria
Telefono
(484) 539-9800
Indirizzo
630 W GERMANTOWN PIKE, PLYMOUTH MEETING
Confronta HRMY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HRMY
Harmony Biosciences Holdings Inc
|
40.51 | 2.28B | 772.53M | 180.90M | 258.73M | 3.1024 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-07-10 | Ripresa | Goldman | Neutral |
| 2025-06-02 | Ripresa | Oppenheimer | Outperform |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-12-17 | Iniziato | H.C. Wainwright | Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-09-10 | Iniziato | UBS | Buy |
| 2024-06-21 | Iniziato | Citigroup | Buy |
| 2024-01-02 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-09-25 | Downgrade | Goldman | Neutral → Sell |
| 2023-09-07 | Iniziato | Berenberg | Buy |
| 2023-04-20 | Iniziato | BofA Securities | Neutral |
| 2022-10-14 | Aggiornamento | Janney | Neutral → Buy |
| 2022-10-14 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-08-03 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-13 | Downgrade | Goldman | Buy → Neutral |
| 2022-07-07 | Iniziato | Mizuho | Buy |
| 2022-04-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-12-01 | Iniziato | Oppenheimer | Outperform |
| 2021-11-04 | Iniziato | Raymond James | Outperform |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-03-29 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-09-14 | Iniziato | Goldman | Neutral |
| 2020-09-14 | Iniziato | Jefferies | Buy |
| 2020-09-14 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Harmony Biosciences Holdings Inc Borsa (HRMY) Ultime notizie
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Harmony Biosciences (NASDAQ:HRMY) Upgraded to "Buy" at Wall Street Zen - MarketBeat
Harmony Biosciences Shows Niche Pharma Momentum Nasdaq Today - Kalkine Media
What analysts say about Harmony Biosciences Holdings Inc stockAutomated Trading Signals & Missed Nvidia? Don’t Miss This One - earlytimes.in
Harmony Advances Pitolisant GR After Bioequivalence Success - Sleep Review
Harmony Biosciences Prepares to Court Investors at Key December Healthcare Conferences - MSN
Harmony Biosciences (HRMY) Shares Promising Phase 3 Trial Results for EPX-100 - GuruFocus
Harmony Biosciences reports positive data for Dravet syndrome drug By Investing.com - Investing.com South Africa
Harmony Biosciences shows seizure reduction in dravet syndrome trial - StreetInsider
Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome - Business Wire
Marshall Wace LLP Increases Stock Holdings in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Harmony’s Next-Gen Narcolepsy Drug Advances With Surprising New Results - MyChesCo
Capital Fund Management S.A. Invests $1.14 Million in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
How supply chain issues affect Harmony Biosciences Holdings Inc. stockDividend Hike & Smart Allocation Stock Reports - Newser
How analysts rate Harmony Biosciences Holdings Inc. stock today2025 Trading Recap & Fast Exit and Entry Strategy Plans - Newser
Harmony Biosciences Holdings, I (HRMY) Stock Forecasts - Yahoo Finance
Harmony Biosciences stock maintains Buy rating at H.C. Wainwright after positive trial data By Investing.com - Investing.com South Africa
Harmony Biosciences stock maintains Buy rating at H.C. Wainwright after positive trial data - Investing.com Nigeria
H.C. Wainwright Reiterates Buy Rating on Harmony Biosciences Holdings Inc. (HRMY) - StreetInsider
Harmony Biosciences to present Dravet syndrome trial data at AES meeting - Investing.com Canada
Harmony Biosciences Valuation Outlook After Recent Share Price Rebound - Yahoo Finance
How Pitolisant GR Progress and New Orexin Agonist Will Impact Harmony Biosciences (HRMY) Investors - Yahoo Finance
Harmony Biosciences (HRMY): Reassessing Valuation After Positive Pitolisant Study and New Orexin 2 Agonist Trial - Yahoo Finance
A Look at Harmony Biosciences (HRMY) Valuation Following Key Pipeline Advancements and Positive Trial Results - simplywall.st
Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting - Business Wire
Harmony Biosciences to present Dravet syndrome trial data at AES meeting By Investing.com - Investing.com South Africa
Harmony Biosciences (Nasdaq: HRMY) to share new EPX-100 Dravet data at 2025 AES - Stock Titan
Prudential Financial Inc. Has $4.79 Million Stake in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Harmony Biosciences Holdings Inc Stock Analysis and ForecastPrice Momentum Alerts & Fast Growing Capital Gains - earlytimes.in
Mizuho Maintains Harmony Biosciences Holdings (HRMY) Outperform Recommendation - Nasdaq
Mizuho raises Harmony Biosciences stock price target to $46 on pipeline progress By Investing.com - Investing.com South Africa
Harmony Biosciences Launches Early Trial of Promising Orexin Agonist - MSN
Mizuho raises Harmony Biosciences stock price target to $46 on pipeline progress - Investing.com Australia
HRMY Upgraded by Mizuho: Price Target Raised to $46 | HRMY Stock News - GuruFocus
Mizuho Raises Price Target on Harmony Biosciences Holdings to $46 From $39, Keeps Outperform Rating - marketscreener.com
Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $46 at Mizuho - StreetInsider
Harmony Biosciences appoints Adam Zaeske as Chief Commercial Officer - MSN
Citi Global Healthcare Conference - marketscreener.com
Boston Partners Takes $19.40 Million Position in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Harmony Biosciences Holdings, Inc. $HRMY Shares Bought by American Century Companies Inc. - MarketBeat
Geode Capital Management LLC Raises Position in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
(HRMY) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
H.C. Wainwright maintains $75 target on Harmony Biosciences stock - MSN
Can Harmony Biosciences Holdings Inc. stock deliver surprise earnings beatEarnings Overview Summary & Verified Swing Trading Watchlist - BỘ NỘI VỤ
Top 5 US Stocks To Buy In December 2025 - Investing.com
Jefferies Financial Group Inc. Purchases 26,326 Shares of Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Harmony Biosciences stock maintains Buy rating at H.C. Wainwright on positive study results - Investing.com Canada
Harmony Biosciences Holdings Inc Azioni (HRMY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):